Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study

Fred Hutchinson Cancer Center267 enrolled

Overview

This trial observes and collects samples from patients before and after stem cell transplantation to learn more about how and why a complication called chronic graft-versus-host disease (GVHD) develops after stem cell transplantation. Performing close observation and various types of testing may enable doctors to notice symptoms or problems sooner than they would normally have been noticed and predict which patients will develop chronic GVHD.

OUTLINE: Patients undergo collection of tears, saliva, buccal mucosa, and fecal samples before stem cell transplant, at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients also undergo collection of blood samples before stem cell transplant, at 1-2, 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients may undergo skin and mouth biopsy over 15-30 minutes before stem cell transplant, at 2-3 and 12 months after stem cell transplant, and at cGVHD onset. Patients undergo digital pictures of the eyes, mouth and skin, and optical coherence tomographybefore stem cell transplant, at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients without standard of care formal pulmonary function test undergo portable spirometry at 2-3, 4, 6, 8, 10, and 12 months after stem cell transplant, and at cGVHD onset. Patients also complete surveys and have their medical records reviewed. After completion of study, patients are followed up periodically.

Study Type

OBSERVATIONAL

Enrollment

267

Conditions

Hematopoietic and Lymphoid Cell Neoplasm

Interventions

Biospecimen CollectionPROCEDURE

Undergo collection of blood, tears, saliva, buccal mucosa, feces, and tissue samples

Optical Coherence TomographyPROCEDURE

Undergo optical coherence tomography

SpirometryPROCEDURE

Undergo portable spirometry

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults age 18 or older * Scheduled for allogeneic HCT from any donor for any indication, with a risk of cGVHD of \> 25% (see below in exclusion criteria for treatment plans with a cGVHD risk \< 25%) * Ability and willingness to comply with the intensive assessment schedule including evaluation every other month at a participating site * Ability to communicate in English or Spanish, to allow completion of patient surveys and clear communication with the study team Exclusion Criteria: * Receipt of umbilical cord blood, bone marrow with post-transplant cyclophosphamide (peripheral blood with post-transplant cyclophosphamide is allowed), anti-thymocyte globulin, alemtuzumab, or ex-vivo T-cell depletion. These patients are excluded because they have a cGVHD risk of \< 25% * Hematologic malignancy with active disease at the time of transplant. Minimal residual disease is allowed * Hematopoietic cell transplant co-morbidity index \> 4 based on parameters known at time of enrollment * Prior allogeneic transplant * Prior autoimmune disease with ongoing symptoms * History of noncompliance * Inability to comply with study requirements due to geographic, logistic, social or any other factors

Locations (7)

University of Florida

Gainesville, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

National Cancer Institute

Bethesda, Maryland, United States

Roswell Park

Buffalo, New York, United States

Outcomes

Primary Outcomes

Levels of cytokines

Will compare the pg/ml levels and trajectories of proteins (IL-1b; IL-4; IL-5; IL-6; IL-8; IL-10; IL-13; IL-17a (pg/mL); TNF; G-CSF; IFNgamma; MCP-1; IL-12p40; GM-CSF; IL-2) between patients who do and do not develop chronic graft versus host disease (cGVHD). Blood will be analyzed separately from saliva and conjunctival washings.

Time frame: Up to 3 years

Onset of cGVHD

Onset of cGVHD will be treated as a time-to-event endpoint, using Cox regression with monthly levels or slopes of the markers entered as time dependent covariates.

Time frame: Up to 3 years

Percentage of cellular populations

Will compare the levels, proportions and trajectories of different cellular populations between those with and without cGVHD, and with different cGVHD organ involvement and symptoms. The following cell subtypes are of highest interest: Th17, FOXP3+ T regulatory cells, FOXP3- T regulatory type 1 (TR1) cells, T follicular helper cells, activated B cells, B regulatory cells, and monocytes but the list may evolve before actual testing.

Time frame: Up to 3 years

Number of patients with tissue alterations in skin, mouth and eyes

Tissue alterations will be classified into Abnormal and Normal, and measured by biopsy and/or advanced bioimaging techniques. Histologic findings, ribonucleic acid (RNA) expression profiles, optical coherence tomography (OCT) findings and digital image interpretations will be compared between patients who do and do not develop cGVHD or who have different cGVHD clinical phenotypes and symptoms.

Time frame: Up to 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.